Crossbow Therapeutics closed a $77 million Series B co‑led by Taiho Ventures and Arkin BioCapital to advance next‑generation T cell engager programs, including lead candidate CBX‑250 developed with MD Anderson. The financing will fund a Phase 1 trial enrolling hematologic malignancy patients, with early clinical readouts targeted by end‑2026. Crossbow’s platform produces TCR‑mimetic antibodies that aim to direct T cells to peptide fragments displayed on cancer cells while reducing off‑target toxicity. The round included strategic investors such as Pfizer Ventures and underscores continued VC interest in engineered immune engager modalities as alternatives to cell therapies.